AstraZeneca Blocks Generics Ahead Of Patent Dispute
AstraZeneca convinced an appeals court Wednesday to keep rival Glenmark's generic version of a billion-dollar diabetes treatment off the market ahead of determination of a patent dispute....To view the full article, register now.
Already a subscriber? Click here to view full article